These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 21888616)
1. Progressive transformation of germinal centers and Hodgkin lymphoma: more insights but maybe more confusion? Sweetenham JW; Polliack A Leuk Lymphoma; 2011 Nov; 52(11):2041-2. PubMed ID: 21888616 [No Abstract] [Full Text] [Related]
2. Efficacy and safety of rituximab treatment in patients with progressive transformation of germinal centers after Hodgkin lymphoma in complete remission post-induction chemotherapy and radiotherapy. Picardi M; Zeppa P; Ciancia G; Pettinato G; Grimaldi F; Fabbricini R; Mainolfi C; Pane F Leuk Lymphoma; 2011 Nov; 52(11):2082-9. PubMed ID: 21663508 [TBL] [Abstract][Full Text] [Related]
3. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. Ban-Hoefen M; Vanderplas A; Crosby-Thompson AL; Abel GA; Czuczman MS; Gordon LI; Kaminski MS; Kelly J; Millenson M; Nademanee AP; Rodriguez MA; Zelenetz AD; Niland J; LaCasce AS; Friedberg JW Br J Haematol; 2013 Nov; 163(4):487-95. PubMed ID: 24111533 [TBL] [Abstract][Full Text] [Related]
4. [Management of lymphoma with respect to pathologic classification: updates and controversies]. Zhu J; Song YQ Zhonghua Bing Li Xue Za Zhi; 2009 Nov; 38(11):724-7. PubMed ID: 20079009 [No Abstract] [Full Text] [Related]
5. Immunoarchitectural patterns of progressive transformation of germinal centers with and without nodular lymphocyte-predominant Hodgkin lymphoma. Hartmann S; Winkelmann R; Metcalf RA; Treetipsatit J; Warnke RA; Natkunam Y; Hansmann ML Hum Pathol; 2015 Nov; 46(11):1655-61. PubMed ID: 26410017 [TBL] [Abstract][Full Text] [Related]
6. PET positive progressive transformation of germinal centers masquerading as relapsed Hodgkin lymphoma post-autograft. Grigg A; Ganju V Leuk Lymphoma; 2006 Apr; 47(4):764-5. PubMed ID: 16886280 [No Abstract] [Full Text] [Related]
7. Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era. King MT; Donaldson SS; Link MP; Natkunam Y; Advani RH; Hoppe RT Int J Radiat Oncol Biol Phys; 2015 May; 92(1):67-75. PubMed ID: 25863755 [TBL] [Abstract][Full Text] [Related]
8. A decade of progress in lymphoma: advances and continuing challenges. Flowers CR; Armitage JO Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):414-23. PubMed ID: 21156459 [TBL] [Abstract][Full Text] [Related]
9. Lymphocyte-predominant Hodgkin lymphoma: what is the optimal treatment? Fanale M Hematology Am Soc Hematol Educ Program; 2013; 2013():406-13. PubMed ID: 24319212 [TBL] [Abstract][Full Text] [Related]
10. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. Evens AM; Kanakry JA; Sehn LH; Kritharis A; Feldman T; Kroll A; Gascoyne RD; Abramson JS; Petrich AM; Hernandez-Ilizaliturri FJ; Al-Mansour Z; Adeimy C; Hemminger J; Bartlett NL; Mato A; Caimi PF; Advani RH; Klein AK; Nabhan C; Smith SM; Fabregas JC; Lossos IS; Press OW; Fenske TS; Friedberg JW; Vose JM; Blum KA Am J Hematol; 2015 Sep; 90(9):778-83. PubMed ID: 26044261 [TBL] [Abstract][Full Text] [Related]
11. The unique entity of nodular lymphocyte-predominant Hodgkin lymphoma: current approaches to diagnosis and management. Hawkes EA; Wotherspoon A; Cunningham D Leuk Lymphoma; 2012 Mar; 53(3):354-61. PubMed ID: 21812538 [TBL] [Abstract][Full Text] [Related]
15. Maintenance rituximab in follicular non-Hodgkin lymphoma: facts and controversies. Nabhan C; Smith SM; Kahl BS Leuk Lymphoma; 2012 May; 53(5):770-8. PubMed ID: 21958083 [TBL] [Abstract][Full Text] [Related]
16. What is the role of stem-cell transplantation for follicular non-hodgkin lymphoma in the rituximab era? Schouten HC J Clin Oncol; 2013 May; 31(13):1617-8. PubMed ID: 23547074 [No Abstract] [Full Text] [Related]
17. A meta-analysis on Rituximab combined CHOP chemotherapy for non-Hodgkin lymphoma in China. Hou S; Yang W Saudi Med J; 2011 Jul; 32(7):675-8. PubMed ID: 21748202 [TBL] [Abstract][Full Text] [Related]
18. The late adverse events of rituximab therapy--rare but there! Ram R; Ben-Bassat I; Shpilberg O; Polliack A; Raanani P Leuk Lymphoma; 2009 Jul; 50(7):1083-95. PubMed ID: 19399690 [TBL] [Abstract][Full Text] [Related]
19. Hodgkin disease subsequent to follicular lymphoma on maintenance rituximab. Scaramucci L; Perrotti A; Niscola P; Fratoni S; Palombi M; Piccioni D; Cupelli L; Tendas A; Dentamaro T; Del Poeta G; De Fabritiis P Leuk Lymphoma; 2007 Sep; 48(9):1878-80. PubMed ID: 17786731 [No Abstract] [Full Text] [Related]
20. Hepatitis B reactivation induced by Rituximab maintenance therapy for lymphoma. Cho CH; Hwang WL; Cheng SB; Lee TY; Teng CL Ann Hematol; 2011 Jan; 90(1):111-2. PubMed ID: 20407894 [No Abstract] [Full Text] [Related] [Next] [New Search]